Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / ADR
-
Shares outstanding
-
55,574,229
-
Total 13F shares
-
60,982,797
-
Share change
-
-4,780,380
-
Total reported value
-
$6,535,152,679
-
Put/Call ratio
-
19%
-
Price per share
-
$107.22
-
Number of holders
-
160
-
Value change
-
-$603,913,240
-
Number of buys
-
70
-
Number of sells
-
95
Institutional Holders of Ascendis Pharma A/S - ADR (ASND) as of Q1 2023
As of 31 Mar 2023,
Ascendis Pharma A/S - ADR (ASND) was held by
160 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
60,982,797 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., Artisan Partners Limited Partnership, FMR LLC, JANUS HENDERSON GROUP PLC, T. Rowe Price Investment Management, Inc., PRICE T ROWE ASSOCIATES INC /MD/, Avoro Capital Advisors LLC, WESTFIELD CAPITAL MANAGEMENT CO LP, WELLINGTON MANAGEMENT GROUP LLP, and GOLDMAN SACHS GROUP INC.
This page lists
160
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.